The global ultrasound-guided breast biopsy market is set to witness remarkable growth, projected to reach a value of US$ 1,090 million by the year 2032, with a robust Compound Annual Growth Rate (CAGR) of 8% during the forecast period. This surge is attributed to the rising incidence of breast cancer cases worldwide and the growing awareness about the significance of early diagnosis.
As of 2022, the ultrasound-guided biopsy market is valued at US$ 720 million, reflecting a steady upward trajectory. The escalating prevalence of breast cancer, coupled with the imperative for early detection, is anticipated to fuel sales in this market segment in the coming years.
Get Access to Sample Now: https://www.futuremarketinsights.com/reports/sample/rep-gb-9580
According to a 2021 report by the World Health Organization (WHO), breast cancer remains a pressing global health concern, with 2.3 million women diagnosed in 2020 and 685,000 succumbing to the disease. With 7.8 million women living with breast cancer in the same year, it stands as the most prevalent cancer worldwide.
Breast cancer manifests in the breast tissue, originating from either the glands responsible for milk production (lobules) or the ducts. Detection of abnormalities or lumps in the breasts is commonly facilitated through methods such as mammography, physical examinations, and ultrasound-guided breast biopsy.
Ultrasound-guided breast biopsy involves the use of ultrasound imaging to guide radiologists in inspecting sites of abnormal cell growth. Typically, this procedure is employed when anomalies like distortions in breast tissue or suspicious solid masses are detected.
The high mortality rate associated with breast cancer and its escalating incidence underscore the critical importance of adopting ultrasound-guided breast biopsy techniques over the assessment period.
Factors Driving Demand in the Ultrasound-Guided Breast Biopsy Market:
- Minimally Invasive: Compared to traditional surgical biopsies, ultrasound-guided procedures are less invasive, resulting in minimal scarring and quicker turnaround times. This translates to a more patient-friendly experience, boosting adoption rates.
- Radiation-Free: Unlike some biopsy techniques, ultrasound doesn't use ionizing radiation, eliminating potential radiation exposure for patients.
- Faster Results & Lower Cost: Ultrasound-guided biopsies provide quicker results compared to some other methods and are generally less expensive, making them an attractive option for both patients and healthcare providers.
- Shorter Recovery: Due to the minimally invasive nature, recovery time from an ultrasound-guided biopsy is typically shorter than with surgical procedures.
Factors Inhibiting the Growth of the Ultrasound-Guided Breast Biopsy Market:
- Bleeding Risk: There's a potential risk of bleeding during the procedure, which can lead to hematoma formation (blood clot). This can be a deterrent for some patients who might prefer alternative biopsy methods.
- Patient Discomfort: While less invasive than surgery, ultrasound-guided biopsies can still cause some discomfort for patients.
- Ultrasound Machine Cost: The cost of ultrasound machines can be a limiting factor for some healthcare facilities, potentially hindering wider adoption of this technology.
Key Companies Profiled:
- Hologic Inc
- Medsurge Ind Private Limited
Key Segments Profiled in the Ultrasound-Guided Breast Biopsy Market Survey:
By Procedure:
- Fine needle aspiration (FNA) ultrasound-guided breast biopsy
- Core needle (CN) ultrasound-guided breast biopsy
- Vacuum-assisted device (VAD) ultrasound-guided breast biopsy
- Wire localization ultrasound-guided breast biopsy
By End User:
- Hospitals
- Clinics
- Diagnostics Laboratories
- Others
By Region:
- North America (U.S., Canada)
- Latin America (Mexico, Brazil)
- Western Europe (Germany, Italy, France, U.K, Spain, Nordic countries, Belgium, Netherlands, Luxembourg)
- Eastern Europe (Russia, Poland)
- Asia-Pacific Excluding Japan(China, India, ASEAN, Australia & New Zealand)
- Japan
- Middle East and Africa (GCC Countries, South Africa, North Africa)
